CN103191215B - 治疗结膜炎的眼药 - Google Patents
治疗结膜炎的眼药 Download PDFInfo
- Publication number
- CN103191215B CN103191215B CN201310117818.7A CN201310117818A CN103191215B CN 103191215 B CN103191215 B CN 103191215B CN 201310117818 A CN201310117818 A CN 201310117818A CN 103191215 B CN103191215 B CN 103191215B
- Authority
- CN
- China
- Prior art keywords
- conjunctivitis
- parts
- eye drops
- eyes
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010010741 Conjunctivitis Diseases 0.000 title claims abstract description 24
- 239000003889 eye drop Substances 0.000 title abstract description 8
- 229940012356 eye drops Drugs 0.000 title abstract 6
- 239000003814 drug Substances 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 241000628997 Flos Species 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 10
- 230000001154 acute effect Effects 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 201000007032 bacterial conjunctivitis Diseases 0.000 abstract description 3
- 201000004484 acute conjunctivitis Diseases 0.000 abstract description 2
- 238000005406 washing Methods 0.000 abstract 2
- 241000132012 Atractylodes Species 0.000 abstract 1
- 240000008365 Celosia argentea Species 0.000 abstract 1
- 235000000722 Celosia argentea Nutrition 0.000 abstract 1
- 235000007516 Chrysanthemum Nutrition 0.000 abstract 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 241000195955 Equisetum hyemale Species 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 abstract 1
- 210000000795 conjunctiva Anatomy 0.000 description 8
- 230000004438 eyesight Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000011010 flushing procedure Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000000744 eyelid Anatomy 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000475481 Nebula Species 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000005282 brightening Methods 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010719 Conjunctival haemorrhage Diseases 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000027993 eye symptom Diseases 0.000 description 1
- 208000013413 gonococcal conjunctivitis Diseases 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960002523 mercuric chloride Drugs 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 206010030861 ophthalmia neonatorum Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种治疗结膜炎的眼药,通过清洗眼部达到消炎治疗治疗结膜炎的效果。治疗结膜炎的眼药,其用下述中药原料制成外用眼药:枣树皮13-17、桑树皮13-17、 木贼草8-12、苍术8-12、菊花10-14、青葙子8-12。本发明通过观察组319例(408眼)急性结膜炎患者用本发明眼药水结膜囊冲洗治疗。证明本发明眼药水通过结囊膜冲洗对急性细菌性结膜炎疗效显著。
Description
技术领域
本发明属于人用药品制造技术领域,特别是治疗结膜炎的眼药。
背景技术
结膜炎(conjunctivitis)是眼科的常见病,但是其发病率目前尚未确定。由于大部分结膜与外界直接接触,因此容易受到周围环境中感染性(如细菌、病毒、及衣原体等)和非感染性因素(外伤、化学物质及物理因素等)的刺激,而且结膜的血管和淋巴组织丰富,自身及外界的抗原容易使其致敏。俗称红眼病。
结膜炎为季节性传染病,好发生在夏秋季,传染性极强,常可暴发流行。结膜炎本身对视力影响一般并不严重,但是当其炎症波及角膜或引起并发症时,可导致视力的损害,甚至失明。另外,结膜炎虽不是什么大毛病,但结膜炎并不是“眼部充血”的唯一原因。眼部充血除了结膜炎外,也要考虑是眼部其它疾病,如角膜破皮、虹彩炎、青光眼、角膜溃疡或是眼睛内部发炎等眼疾之警讯,不可以大意。
目前的治疗手段有:
1、冲洗结膜囊:结膜囊内有分泌物时,进行冲洗,其作用主要是清洁,所用清洗剂应为无刺激性,常用者为生理盐水、2%~3%硼酸溶液或1: 5000~ 1 :10000升汞(或高锰酸钾)溶液,用洗眼壶冲洗。冲洗液须有适宜的温度。冲洗时,翻转眼睑,冲洗结膜面,同时用手指推动上下脸,使穹窿的分泌物也被冲出,同时头转向同侧,避免冲洗液流人对侧眼。
2、局部用药:①抗菌药物或抗病毒滴眼剂:根据病原学诊断,选择相应的治疗药物。②眼膏:眼膏的药物浓度高,作用时间长,适用于睡前涂。③腐蚀剂:腐蚀剂有很强的杀菌力,同时也腐蚀结膜表层组织引起坏死,如硝酸银,应用时直接涂抹患处,切不可触及角膜,常用0.5~1% 硝酸银,滴眼时要翻转眼睑,将眼液滴于睑结膜上,滴眼后稍停片刻,即用生理盐水冲洗.或用棉签蘸少量药液,涂于睑结膜表面,随即用生理盐水冲洗。对于急性期分泌物多者,效果很好,但不可长期应用。
3、全身治疗:对于严重的结膜炎,如淋球菌性结膜炎、沙眼等,需结合全身用药治疗
在上述治疗方法中,尤以局部给药治疗因为给要少、简单方便最常用,但所用药物以西药为主,只要目的是消炎,对于结膜炎容易造成复发。
发明内容
本发明目的是发明一种治疗结膜炎的眼药,通过清洗眼部达到消炎治疗治疗结膜炎的效果。
治疗结膜炎的眼药,其用下述中药原料制成外用眼药:
枣树皮13-17、桑树皮13-17、 木贼草8-12、苍术8-12、菊花10-14、青葙子8-12。
优先推荐用下述中药原料制成外用眼药:枣树皮15、桑树皮15、 木贼草10、苍术0、菊花12、青葙子10。
本发明各组分功效如下:
枣树皮--- 止血、明目、治痢止泻、镇咳祛痰;
桑树皮---泻肺平喘、利水消肿;
木贼草--- 疏风热、退翳膜 ;
苍术--- 祛风胜湿、健脾止泻、散寒、除障明目 ;
菊花--- 疏散风热、平肝明目;
青葙子--- 清肝明目、退翳,用于肝热目赤,眼生翳膜,视物昏花,肝火眩晕。
本发明采用枣树皮、青葙子、菊花明目;采用木贼草、苍术祛风寒,再用桑树皮利水消肿,总体具有消炎明目作用,对结膜炎具有较好治疗效果。
本发明通过观察组319例(408眼)急性结膜炎患者用本发明眼药水结膜囊冲洗治疗。证明本发明眼药水通过结囊膜冲洗对急性细菌性结膜炎疗效显著。
具体实施方式
配方1:枣树皮15、桑树皮15、 木贼草10、苍术0、菊花12、青葙子10。
配方2:枣树皮13、桑树皮17、 木贼草8、苍术12、菊花10、青葙子12
配方3:枣树皮17、桑树皮13、 木贼草12、苍术8、菊花14、青葙子8。
上述配方药物清洗后提取液制成外用眼药水剂。
本发明实施例治疗结膜炎319例(408眼)临床报告
1 资料与方法
1.1 诊断及观察指标、评分标准 诊断标准根据全国高等医学院校教材《眼科学》和《眼科全书》而定。发病急,病程短;自觉流泪、异物感、灼热感或痒痛等。结膜充血,分泌物多。先为粘液性,后呈脓性,可发生结膜下出血。细胞学检查是多形核白细胞增多。观察指标及评分标准:观察患者眼痛、流泪,分泌物、眼睑红肿,睑结膜充血,球结膜充血共6项,根据程度不同分为0,1,2,3分4个等级。
1.2 一般资料 观察组为结膜炎319例(408眼),病程1~2天,用药前均经结膜刮片细胞学检查确诊,并未用过其他药物治疗。
1.3 治疗方法 观察组用本发明制剂(按照配方1制备)20ml加入500ml生理盐水溶液中,结膜囊冲洗双眼约100ml,每日2次。疗程3天,观察眼部症状及体征变化,每天评分记录1次,疗程结束后判断疗效。一月后随访。
2 结果
2.1 疗效标准 痊愈:症状体征全部消失; 显效:全部症状消失或主要症状体征消失;有效:主要症状体征基本消失;无效:各方面症状体征无改善。
2.2疗效统计
痊愈301眼,痊愈率74%;显效59眼, 有效45眼,无效3眼,总有效率99%。
同时治疗后主要症状:痒痛,流泪,分泌物,眼睑红肿,睑结膜充血,球结膜充血等基本消失。
一个月后参与随访290例(人)只有3例有过症状复发,并未采取治疗措施自愈,其余患者未见症状复发。
3、结论
本发明总体具有消炎明目作用,通过结囊膜冲洗对急性细菌性结膜炎疗效显著。
Claims (1)
1.治疗结膜炎的眼药,其特征是用下述中药原料制成外用眼药:枣树皮13-17、桑树皮13-17、木贼草8-12、苍术8-12、菊花10-14、青葙子8-12。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310117818.7A CN103191215B (zh) | 2013-04-07 | 2013-04-07 | 治疗结膜炎的眼药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310117818.7A CN103191215B (zh) | 2013-04-07 | 2013-04-07 | 治疗结膜炎的眼药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103191215A CN103191215A (zh) | 2013-07-10 |
CN103191215B true CN103191215B (zh) | 2014-04-16 |
Family
ID=48714149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310117818.7A Expired - Fee Related CN103191215B (zh) | 2013-04-07 | 2013-04-07 | 治疗结膜炎的眼药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103191215B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104587076A (zh) * | 2015-01-13 | 2015-05-06 | 青岛市中心医院 | 一种治疗结膜炎的中药洗液 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101199685A (zh) * | 2007-12-12 | 2008-06-18 | 叶志平 | 一种治疗慢性结膜炎的熏洗药物 |
-
2013
- 2013-04-07 CN CN201310117818.7A patent/CN103191215B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101199685A (zh) * | 2007-12-12 | 2008-06-18 | 叶志平 | 一种治疗慢性结膜炎的熏洗药物 |
Non-Patent Citations (2)
Title |
---|
孟青青等.过敏性结膜炎的治疗研究进展.《中国中医眼科杂志》.2012,第22卷(第6期), |
过敏性结膜炎的治疗研究进展;孟青青等;《中国中医眼科杂志》;20121231;第22卷(第6期);第446-449页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103191215A (zh) | 2013-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102512603B (zh) | 一种治疗急性传染性结膜炎的中药组合物 | |
CN102362924B (zh) | 一种治疗眼科疾病的药物组合物及其制备方法 | |
CN111544390B (zh) | 治疗睑板腺功能障碍和/或过敏性结膜炎的中药制剂及超声雾化和纳米喷雾制剂和制备方法 | |
CN102688301B (zh) | 一种治疗急性结膜炎的中药洗剂及其制备方法 | |
CN100388923C (zh) | 一种治疗急性角膜炎、缓解视疲劳的中药制剂及其制备工艺 | |
CN103191215B (zh) | 治疗结膜炎的眼药 | |
CN101167884B (zh) | 一种内服用于治疗白内障的中药配方 | |
CN103948789A (zh) | 一种治疗结膜炎的滴眼液 | |
CN103211869B (zh) | 一种用于急性结膜炎的中药滴眼剂及其制备方法 | |
CN105106318A (zh) | 一种治疗干眼症的中药组合物及其制备方法 | |
CN103877424B (zh) | 一种治疗沙眼的中药药水及制备方法 | |
CN104027565A (zh) | 一种治疗结膜炎的内服中药 | |
CN104274734B (zh) | 一种治疗急性眼结膜炎的中药组合物 | |
CN104173732A (zh) | 一种治疗急性结膜炎的中药制剂 | |
CN103961644A (zh) | 一种治疗结膜炎的内服汤剂 | |
CN106822671A (zh) | 用于治疗结膜炎的药物 | |
CN103550455B (zh) | 一种治疗青光眼的中药 | |
CN1108130A (zh) | 一种治白内障药及其制备方法 | |
CN105521145A (zh) | 一种眼药组合物 | |
CN104523850A (zh) | 一种治疗鼻炎、鼻窦炎的药物组合物 | |
CN104940384B (zh) | 一种治疗结膜炎的中药组合物及其制备方法 | |
CN105708976A (zh) | 一种治疗乙肝的中药组合物及其制备方法 | |
CN105596717A (zh) | 一种治疗疱疹性角膜炎的中药制剂 | |
CN104056068A (zh) | 一种治疗慢性结膜炎的中药滴眼剂 | |
CN105055764A (zh) | 一种用于治疗慢性闭角型青光眼的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140416 Termination date: 20150407 |
|
EXPY | Termination of patent right or utility model |